

References

1. **Abrámoff M.D., Alward W.L.M., Greenlee E.C., Shuba L., Kim C.Y., Fingert J.H., and Kwon Y.H. (2007):** Automated segmentation of the optic disc from stereo color photographs using physiologically plausible features, *Investigative Ophthalmology & Visual Science*; 48(4): 1665-1673.
2. **Aisenbrey S., Ziemssen F., Volker M., et al. (2007):** Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*; 245: 941-948.
3. **Alam S., Zawadzki R.J., Choi S., et al. (2006):** Clinical application of rapid serial Fourier-domain optical coherence tomography for macular imaging. *Ophthalmology*; 113: 1425-1431.
4. **Arevalo J.F., and Garcia R.A. (2008):** Clinical Applications of Optical Coherence Tomography in Age-Related Macular Degeneration. In *Retinal Angiography and Optical Coherence Tomography*, 1st ed. Springer, New York, 253-265.
5. **Arevalo J.F., Fernandez C.F., Fernandez C.F., Sanchez J.G., and Garcia R.A.(2008):** Optical Coherence Tomography in Macular Diseases. In *Retinal Angiography and Optical Coherence Tomography*, 1st ed. Springer, New York, 223-238.
6. **Arevalo J.F., Krivoy D., and Fernandez C.F.(2008):** How Does Optical Coherence Tomography Work? Basic Principles. In *Retinal Angiography and Optical Coherence Tomography*, 1st ed. Springer, New York, 217-222.

7. **Arichika S., Hangai M., and Yoshimura N.(2010):** Correlation between thickening of the inner and outer retina and visual acuity in patients with epiretinal membrane. *Retina*; 30: 503-508.
8. **Barthelmes D., Sutter F.K., and Gillies M.C.(2008):** Differential optical densities of intraretinal spaces. *Invest. Ophthalmol. Vis. Sci.*; 49: 3529–3534.
9. **Baskin D.E.(2010):** Optical Coherence Tomography in Diabetic Macular Edema. *Curr. Opin. Ophthalmol.*; 21: 172-177.
10. **Baumal C.R., and Kim R.W.(2008):** The Role of Optical Coherence Tomography in the Evaluation of Ocular Photodynamic Therapy. In *Retinal Angiography and Optical Coherence Tomography*, 1st ed. Springer, New York, 267-278.
11. **Baumal C.R., Puliafito C.A., Pierrot L., et al.(1996):** Photodynamic therapy (PDT) of experimental choroidal neovascularization with tin ethyl etiopurpurin (SnET2). *Invest Ophthalmol Vis Sci*;suppl 37: S122.
12. **Baumann M., Gentile R.C., Liebmann J.M., and Ritch R.(1998):** Reproducibility of retinal thickness measurements in normal eyes using optical coherence tomography. *Ophthalmic Surg Lasers*; 29: 280-285.
13. **Beareilly S., Chau F.Y., Koreishi A., Stinnett S.S., Izatt J.A., and Toth C.A.(2009):** Spectral domain optical coherence tomography imaging of geographic atrophy margins. *Ophthalmology*; 116: 1762-1769.
14. **Bernardes R., Santos T., and Cunha-Vaz J.(2008):** Increased-resolution OCT thickness mapping of the human macula: a statistically based registration. *Invest. Ophthalmol. Vis. Sci.*; 49: 2046-2052.
15. **Bhagat N., Grigorian R.A., Tutela A., and Zarbin M.A.(2009):** Diabetic macular edema: pathogenesis and treatment. *Surv. Ophthalmol.*; 54: 1-32.

16. **Bolz M, Ritter M, Schneider M, Simader C, Scholda C, Schmidt-Erfurth U (2009):** A Systematic Correlation of Angiography and High-Resolution Optical Coherence Tomography in Diabetic Macular Edema. *Ophthalmology*; 116: 66-72.
17. **Bolz M., Kriechbaum K., Simader C., et al.(2010):** In vivo retinal morphology after grid laser treatment in diabetic macular edema. *Ophthalmology*; 117: 538-544.
18. **Brar M., Kozak I., Cheng L., Bartsch D.U., Yuson R., Nigam N., Oster S.F., Mojana F., and Freeman W.R.(2009):** Correlation between spectral-domain optical coherence tomography and fundus autofluorescence at the margins of geographic atrophy. *Am. J. Ophthalmol.*; 148: 439–444.
19. **Bressler N.M., Bressler S.B., Alexander J., Javornik N., Fine S.L., and Murphy R.P.(1991):** Loculated fluid. A previously undescribed fluorescein angiographic finding in choroidal neovascularization associated with macular degeneration. Macular Photocoagulation Study Reading Center. *Arch. Ophthalmol.*; 109: 211–215.
20. **Bressler N.M., Bressler S.B., and Fine S.L.(1988):** Age-related macular degeneration. *Surv. Ophthalmol.*; 32: 375–413.
21. **Bressler N.M., Bressler S.B., and Fine S.L.(2001):** Neovascular (Exudative) Age Related Macular Degeneration. In *Retina*., 3rd ed., St. Mosby, 1100–1135.
22. **Brezinski M.(2006):** Optical Coherence Tomography Theory. In *Optical Coherence Tomography: Principles and applications*, 1st ed. Elsevier, London, 97-145

23. **Brown D.M., Kaiser P.K., Michels M., et al.(2006):** Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N. Engl. J. Med.*; 355(14): 1432–1444.
24. **Browning D.J., Fraser C.M., and Propst B.W.(2008):** The variation in optical coherence tomography-measured macular thickness in diabetic eyes without clinical macular edema. *Am. J. Ophthalmol.*; 145: 889–893.
25. **Browning D.J., Glassman A.R., et al.(2007):** Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology*; 114: 525–536.
26. **Browning D.J., McOwen M.D., Bowen R.M., and O'Marah TL.(2004):** Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. *Ophthalmology*; 111: 712–715.
27. **BuAbbud J.C., Al-latayfeh M.M., and Sun J.K.(2010):** Optical Coherence Tomography Imaging for Diabetic Retinopathy and Macular Edema. *Curr. Diab. Rep.*; 10: 264–269.
28. **Budenz, D.L., Michael, A., Chang, R.T., McSoley, J., and Katz, J., (2005):** Sensitivity and specificity of the Stratus OCT for perimetric glaucoma. *Ophthalmology*; 112: 3-9.
29. **Catier A., Tadayoni R., Paques M., et al., (2005):** Characterization of macular oedema from various aetiologies by optical coherence tomography. *Am J Ophthalmol*; 140: 200–206.
30. **Chang L.K., Koizumi H., and Spaide R.F.(2008):** Disruption of the photoreceptor inner segment-outer segment junction in eyes with macular holes. *Retina*; 28: 969–975.

31. **Chen R. W.S., Fujimoto J.G., and Duker J.S.(2008):** Spectral/Fourier Domain Optical Coherence Tomography. In Retinal Angiography and Optical Coherence Tomography, 1st ed. Springer, New York, 439-452.
32. **Chen T.C., Cense B., Pierce M.C., et al., (2005):** Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch. Ophthalmol., 123: 1715–1720.
33. **Chen T.C., Zeng A., Sun W., Mujat M., and de Boer J.F.(2008):** Spectral domain optical coherence tomography and glaucoma. Int Ophthalmol Clin 48:29–45
34. **Choma M.A., Hsu K., and Izatt J.A., (2005):** Swept source optical coherence tomography using an all-fiber 1300-nm ring laser source. J. Biomed. Opt. 10,044009.
35. **Choma M.A., Sarunic M.V., Yang C., et al.(2003):** Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express; 11: 2183-2189.
36. **Chong G.T., Farsiu S., Freedman S.F., Sarin N., Koreishi A.F., and Izatt J.A.(2009):** Toth CA: Abnormal foveal morphology in ocular albinism imaged with spectral-domain optical coherence tomography. Arch Ophthalmol; 127: 37– 44.
37. **Chung E.J., Lew Y.J., Lee H., and Koh H.J.,(2008):** OCT-guided hyaloid release for vitreomacular traction syndrome. Korean J. Ophthalmol. 22, 169-173
38. **Coscas F., Coscas G., Souied E., et al.(2007):** Optical coherence tomography identification of occult choroidal neovascularisation in age-related macular degeneration. Am. J. Ophthalmol.; 144: 592–9.

39. **Costa R.A., Farah M.E., Cardillo J.A., Calucci D., and Williams G.A.(2003):** Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. *Retina*; 23: 159–165.
40. **Cukras C., Wang Y.D., Meyerle C.B., Forooghian F., Chew E.Y., Wong W.T.(2010):** Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices. *Eye*, E-pub ahead of print. *Eye*; 24: 775-783.
41. **Curcio C.A., and Allen K.A.(1990):** Topography of ganglion cells in human retina. *J. Comp. Neurol.*; 300: 5–25.
42. **Dayani P.N., Maldonado R., Farsiu S., and Toth C.A.,(2009):** Intraoperative use of handheld spectral domain optical coherence tomography imaging in macular surgery. *Retina* 29, 1457-1468
43. **Drexler W., (2004) :** Ultrahigh-resolution optical coherence tomography. *J Biomed Opt* ; 9: 47–74.
44. **Drexler W., Sattmann H., Hermann B. et al., (2003):** Enhanced visualization of macular pathology with the use of ultrahigh resolution optical coherence tomography. *Arch Ophthalmol*; 121: 695–706
45. **Duker J.S., Puliafito C.A., Wilkins J.R., et al(1995):** Imaging fellow eyes in patients diagnosed with idiopathic macular holes using optical coherence tomography (OCT). *Ophthalmology*; 102(suppl.): 118.
46. **Einbock W., Berger L., Wolf-Schnurrbusch U., Fleischhauer J., and Wolf S.(2008):** Predictive factors for visual acuity of patients with diabetic macular edema interpreted from the spectralis HRA+OCT (Heidelberg Engineering). *Invest Ophthalmol Vis Sci*; 49: 3473.

47. **Elman MJ, and Fine S.L.(1994):** Exudative Age- Related Macular Degeneration. In Retina, 2nd ed. St. Louis, Mosby,1071-1102.
48. **Falkner-Radler C.I., Glittenberg C., and Binder S.,(2009):** Spectral domain high-definition optical coherence tomography in patients undergoing epiretinal membrane surgery. Ophthalmic Surg. Lasers Imaging 40, 270-276
49. **Fernandes L.H., Freund K.B., Yannuzzi L.A., et al.(2002):** The nature of focal areas of hyperfluorescence or hot spots imaged with indocyanine green angiography. Retina; 22: 557–568.
50. **Fernández D.C., Salinas H.M., and Puliafito C.A. (2005):** Automated detection of retinal layer structures on optical coherence tomography images, Optics Express; 13(25): 10200-10216.
51. **Ferrara N., Damico L., Shams N., et al.(2006):** Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina; 26(8): 859–870.
52. **Fleckenstein M., Schmitz-Valckenberg S., Adrion C., Kramer I., Eter N., Helb H.M., Brinkmann C.K., Charbel I.P., Mansmann U., and Holz F.G.(2010):** Tracking progression using spectral domain optical coherence tomography in geographic atrophy due to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci.; 51: 3846-385.
53. **Fong D.S., Ferris F.L., Davis M.D., and Chew E.Y.(1999):** Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol; 127: 137–141.
54. **Forooghian F., Cukras C., Meyerle C.B., Chew E.Y., and Wong W.T.(2008):** Evaluation of time domain and spectral domain optical

- coherence tomography in the measurement of diabetic macular edema. *Invest Ophthalmol Vis Sci*; 49: 4290–4296.
55. **Framme C., Panagakis G., and Birngruber R.(2010):** Effects on choroidal neovascularization after anti-VEGF upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. *Invest. Ophthalmol. Vis. Sci.* 51, 1671-1676
56. **Freeman S.R., Kozak I., Cheng L., Bartsch D.U., Mojana F., Nigam N., Brar M., Yuson R., and Freeman W.R.(2010):** Optical coherence tomography-raster scanning and manual segmentation in determining drusen volume in age-related macular degeneration. *Retina* 30, 431-435.
57. **Fujimoto H., Gomi F., Wakabayashi T., Sawa M., Tsujikawa M., and Tano Y.(2008):** Morphologic changes in acute central serous chorioretinopathy evaluated by Fourier-domain optical coherence tomography. *Ophthalmology*; 115: 1494–1500.
58. **Fung A., London N., and Rosenfeld Ph.(2008):** The Role of Optical Coherence Tomography in Anti-Vascular Endothelial Growth Factor Therapies. In *Retinal Angiography and Optical Coherence Tomography*, 1st ed. Springer, New York, 279-288.
59. **Fung A.E., Rosenfeld P.J., and Reichel E.(2006):** The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. *Br J Ophthalmol*; 90: 1344–1349 .
60. **Gabriele M.L., Ishikawa H., G. Wollstein G., et al.(2007):** Peripapillary nerve fiber layer thickness profile determined with high speed, ultrahigh resolution optical coherence tomography high-density scanning. *Invest. Ophthalmol. Vis. Sci.* 48(7), 3154-3160.
61. **Gabriele M.L., Ishikawa H., Wollstein G., Bilonick R.A., Townsend K.A., Kagemann L., Wojtkowski M., Srinivasan V.J., Fujimoto J.G.,**

- Duker J.S., and Schuman J.S.(2008):** Optical coherence tomography scan circle location and mean retinal nerve fiber layer measurement variability. *Invest. Ophthalmol. Vis. Sci.* 49, 2315-2321
62. **Galeotti J., Sajjad A., Wang B., Kagemann L., Shulka G., Siegel M., Wu B., Klatzky R., Wollstein G., Schuman J.S., and Stetten G., (2010):** The OCT penlight: insitu image guidance for microsurgery. *Proceedings of the SPIE*; 7625: 762502-762506.
63. **Gallemore R.P., Jumper J.M., McCuen 2nd B.W., Jaffe G.J., Postel E.A., and Toth C.A.(2000):** Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. *Retina* 20, 115-120.
64. **Gass J.D.(1988):** Idiopathic senile macular hole. Its early stages and pathogenesis. *Arch Ophthalmol*; 106: 629–639.
65. **Gass J.D.(1995):** Reappraisal of biomicroscopic classification of stages of development of a macular hole. *Am J Ophthalmol*; 119: 752–759.
66. **Gass J.D., and Joondeph B.C.(1990):** Observations concerning patients with suspected impending macular holes. *Am. J. Ophthalmol.*; 109: 638–646.
67. **Gass J.D.M.(1997):** Pathophysiologic and histopathologic bases for interpretation of fluorescein angiography. In *Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment*, 4th ed. St. Louis: Mosby, 40–41.
68. **Gaucher D., Sebah C., Erginay A., et al.(2008):** Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. *Am J Ophthalmol*; 145: 289–296.
69. **Gaucher D., Tadayoni R., Erginay A., et al.(2005):** Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. *Am J Ophthalmol*; 139: 807–813.

70. **Gilgen H.H., Novak R.P, and Hodel W.R. (1989):** Submillimeter optical reflectometry . IEEE J Lightwave technol; 7: 1225-1233.
71. **Giovannini A., Amato G., and Mariotti C.(2002):** The macular thickness and volume in glaucoma: an analysis in normal and glaucomatous eyes using OCT. Acta Ophthalmol Scand Suppl.; 236: 34–36.
72. **Giovannini A., Amato G., Mariotti C., and Scassellati-Sforzolini B.(2000):** Optical coherence tomography in the assessment of retinal pigment epithelial tear. Retina; 20: 37–40.
73. **Glenn J Jaffe & Joseph Caprioli (2004):** Optical coherence tomography to detect and manage retinal diseases and glaucoma. Am J Ophthalmol; 137:156-169.
74. **González-García A.O., Vizzeri G., Bowd C., Medeiros F.A., Zangwill L.M., and Weinreb R.N. (2009):** Reproducibility of RTVue retinal nerve fiber layer thickness and optic disc measurements and agreement with Stratus optical coherence tomography measurements. Am. J. Ophthalmol. 147:1067–1074.
75. **Gragoudas E.S., Adamis A.P., Cunningham E.T. Jr., et al.(2004):** Pegaptanib for neovascular age-related macular degeneration. N Engl J Med; 351(27): 2805–2816.
76. **Greenfield D.S., Bagga H., and Knighton R.W.(2003):** Macular thickness changes in glaucomatous optic neuropathy detected using optical coherence tomography. Arch Ophthalmol.; 121: 41–46.
77. **Gregori N.Z., Berrocal A.M., Gregori G., Murray T.G., Knighton R.W., Flynn H.W. Jr., Dubovy S., Puliafito C.A., and Rosenfeld P.J.(2009):** Macular spectral- domain optical coherence tomography in patients with X linked retinoschisis. Br J Ophthalmol; 93: 373–378.

78. **Guan K., Hudson C., Flanagan J.G. (2004):** Comparison of Heidelberg retina tomography II and the retinal thickness analyser in the assessment of diabetic macular oedema. *Invest Ophthalmol Vis Sci.*, 45: 610–616.
79. **Guedes V., Schuman J.S., Hertzmark E., et al.(2003):** Optical coherence tomography measurement of macular and nerve fiber layer thickness in normal and glaucomatous human eyes. *Ophthalmology.*; 110: 177-189.
80. **Gupta V., Gupta A., Gupta P., and Sharma A.(2009):** Spectral- domain cirrus optical coherence tomography of choroidal striations seen in the acute stage of Vogt-Koyanagi-Harada disease. *Am. J. Ophthalmol.*; 147: 148-153.
81. **Hangai M., Ojima Y., Gotoh N., Inoue R., Yasuno Y., Makita S., Yamanari M., Yatagai T., Kita M., and Yoshimura N(2007):** Three-dimensional imaging of macular holes with high-speed optical coherence tomography. *Ophthalmology*; 114: 763–773.
82. **Hassenstein A., Ruhl R., and Richard G.(2001):** Optical coherence tomography in geographic atrophy—a clinicopathologic correlation. *Klin Monatsbl Augenheilkd*; 218(7): 503–509.
83. **Hee M.R., Bauman C.R., Puliafito C.A., et al.(1996):** Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. *Ophthalmology*; 103: 1260–1270.
84. **Hee M.R., Izatt J.A., Swanson E.A., et al.(1995):** Optical coherence tomography of the human retina. *Arch Ophthalmol*; 113: 325–332.
85. **Hee M.R., Puliafito C.A., Duker J.S., et al.(1998):** Topography of diabetic macular edema with optical coherence tomography. *Ophthalmology*; 105: 360–370.

86. **Hee M.R., Puliafito C.A., Wong C., et al.(1995):** Optical coherence tomography of central serous chorioretinopathy. *Am J Ophthalmol*; 120: 65–74.b
87. **Hee M.R., Puliafito C.A., Wong C., et al.(1995):** Quantitative assessment of macular edema with optical coherence tomography. *Arch Ophthalmol*; 113: 1019–1029.a
88. **Huang D. (2009):** OCT Terminology Demystified. *Ophthalmology Management* 13(4):33-36
89. **Huang D., Swanson E.A., Lin C.P., Schuman J.S., Stinson W.G., Chang W., Hee M.R., Flotte T., Gregory K., and Puliafito C.A. (1991):** Optical coherence tomography, *Science*; 254(5035): 1178-1181.
90. **Husain D., Kramer M., Kenny A.G., et al.(1999):** Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. *Invest Ophthalmol Vis Sci*; 40: 2322–2331.
91. **Inoue M., Watanabe Y., Arakawa A., Sato S., Kobayashi S., and Kadonosono K.(2009):** Spectral-domain optical coherence tomography images of inner/outer segment junctions and macular hole surgery outcomes. *Graefes Arch Clin Exp Ophthalmol*; 247: 325-330.
92. **Ip M., Garza-Karren C., Duker J.S., et al.(1999):** Differentiation of degenerative retinoschisis from retinal detachment using optical coherence tomography. *Ophthalmology*; 106: 600-605.
93. **Ishikawa H., Stein D.M., Wollstein G., Beaton S., Fujimoto J.G., and Schuman J.S.(2005):** Macular segmentation with optical coherence tomography. *Invest Ophthalmol Vis Sci*; 46: 2012-2017.

94. **Jaffe G.J., and Caprioli J.(2004):** Related articles, links abstract optical coherence tomography to detect and manage retinal disease and glaucoma. *Am. J. Ophthalmol.*; 137: 156-169.
95. **Jiao S.L., Knighton R., Huang X.R., et al., (2005):** Simultaneous acquisition of sectional and fundus ophthalmic images with spectral-domain optical coherence tomography. *Opt. Express.*, 13:444-452.
96. **Kellner S., Weinitz S., and Kellner U.(2009):** Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence. *Br J Ophthalmol*; 93: 1444-1447.
97. **Khanifar A.A., Koreishi A.F., Izatt J.A., and Toth C.A.(2008):** Drusen ultrastructure imaging with spectral domain optical coherence tomography in age-related macular degeneration. *Ophthalmology*; 115: 1883-1890.
98. **Kim B.Y., Smith S.D., and Kaiser P.K.(2006):** Optical coherence tomographic patterns of diabetic macular edema. *Am J Ophthalmol*; 142:405-412.
99. **Kim N.R., Kim Y.J., Chin H.S., Moon Y.S.(2009):** Optical coherence tomographic patterns in diabetic macular oedema: prediction of visual outcome after focal laser photocoagulation. *Br J Ophthalmol*; 93: 901-905.
100. **Kim S.G., Lee S.C., Seong Y.S., Kim S.W., and Kwon O.W.(2003):** Choroidal neovascularization characteristics and its size in optical coherence tomography. *Yonsei Med J*; 44: 821-827.
101. **Kirber W.M., Nichols C.W., Grimes P.A., Winegrad A.I., Laties A.M.(1980):** A permeability defect of the retinal pigment epithelium.

- Occurrence in early streptozocin diabetes. *Arch Ophthalmol*; 98: 725–728.
102. **Knudsen S.T., Bek T., Logstrup poulsen p., et al., (2003):** effects of losartan on diabetic maculopathy in type 2 diabetic patients: a randomized, double-masked study. *Internal Medicine* ; 254: 147–158
103. **Ko T.H., Fujimoto J.G., Duker J.S., et al., (2004):** Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular hole pathology and repair. *Ophthalmology*; 111: 2033–2043.
104. **Ko T.H., Fujimoto J.G., Schuman J.S., et al., (2005) :** Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. *Ophthalmology*; 112; 1922.
105. **Ko T.H., Witkin A.J., Fujimoto J.G., et al. (2006):** Ultrahigh-resolution optical coherence tomography of surgically closed macular holes. *Arch Ophthalmol* 124: 827-836
106. **Koenig F, Soubrane G, and Coscas G.(1984):** Angiographic aspects of senile macular degeneration: spontaneous course. *J. Fr. Ophthalmol.*; 7: 93–98.
107. **Koizumi H., Maguire J.I., and Spaide R.F.(2009):** Spectral domain optical coherence tomographic findings of occult macular dystrophy. *Ophthalmic Surg. Lasers Imaging*; 40: 174– 176.
108. **Koizumi H., Spaide R.F., Fisher Y.L., Freund K.B., Klancnik J.M. Jr., and Yannuzzi L.A.(2008):** Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral- domain optical coherence tomography. *Am J Ophthalmol*; 145: 509–517.
109. **Koleva-Georgieva, D., and Sivkova, N.,(2009):** Assessment of serous macular detachment in eyes with diabetic macular edema by use of

- spectral-domain optical coherence tomography. *Graefes Arch. Clin. Exp. Ophthalmol.* 247, 1461-1469
110. **Konidakis V., Androudi S., and Brazitikos P.(2009):** Myopic traction maculopathy: study with spectral domain optical coherence tomography and review of the literature. *Hippokratia*; 13: 110–113.
111. **Krivosic V., Tadayoni R., Massin P., Erginay A., and Gaudric A.(2009):** Spectral domain optical coherence tomography in type 2 idiopathic perifoveal telangiectasia. *Ophthalmic Surg Lasers Imaging*; 40: 379–384.
112. **Lederer D.E., Schuman J.S., Hertzmark E., et al.(2003):** Analysis of macular volume in normal and glaucomatous eyes using optical coherence tomography. *Am. J. Ophthalmol.*;135: 838–843.
113. **Legarreta J.E., Gregori G., Knighton R.W., Punjabi O.S., Lalwani G.A., and Puliafito C.A.,(2008):** Three-dimensional spectral-domain optical coherence tomography images of the retina in the presence of epiretinal membranes. *Am. J. Ophthalmol.*; 145: 1023-1030
114. **Leng T., Lujan B.J., Yoo S.H., and Wang J.,(2008):** Three-dimensional spectral domain optical coherence tomography of a clear corneal cataract incision. *Ophthalmic Surg. Lasers Imaging*; 39: S132-S134
115. **Leung C.K., Cheung C.Y., and Weinreb R.N.(2008):** Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. *Invest Ophthalmol Vis Sci.*; 49: 2223-2301.
116. **Leung C.K., Cheung C.Y., Weinreb R.N., et al.(2009):** Retinal nerve fiber layer imaging with spectral-domain optical coherence tomography a variability and diagnostic performance study. *Ophthalmology*; 116: 1257-1263.

117. **Li S., Wang X., Li Sh., Wu G., and Wang N.(2010):** Evaluation of optic nerve head and retinal nerve fiber layer in early and advance glaucoma using frequency-domain optical coherence tomography. *Graefes Arch. Clin. Exp. Ophthalmol.* 248:429–434
118. **Lim J.I., Tan O., Fawzi A.A., Hopkins J.J., Gil- Flamer J.H., and Huang D.(2008):** A pilot study of Fourier- domain optical coherence tomography of retinal dystrophy patients. *Am. J. Ophthalmol.*; 146: 417-426.
119. **Lin D., Leung C.K., Weinreb R.N., Cheung C.Y., Li H., and Lam D.S.(2009):** Longitudinal evaluation of optic disc measurement variability with optical coherence tomography and confocal scanning laser ophthalmoscopy. *J. Glaucoma*; 18: 101-106.
120. **Liu B., and Brezinski M. E.(2007):** Theoretical and practical considerations on detection performance of time domain, Fourier domain, and swept source optical coherence tomography. *J. Biomed. Opt.*; 12: 044007.
121. **Lujan B.J., Rosenfeld P.J., Gregori G., Wang F., Knighton R.W., Feuer W.J., and Puliafito C.A.(2009):** Spectral domain optical coherence tomographic imaging of geographic atrophy. *Ophthalmic Surg Lasers Imaging*; 40: 96–101.
122. **Macular photocoagulation study group(1991):** Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. *Arch Ophthalmol* ; 109: 1242–1257.
123. **Mai Takagishi, Kazuyuki Hirooka,, Tetsuya Baba, Masanori Mizote, and Fumio Shiraga (2011):** Comparison of Retinal Nerve Fiber Layer Thickness Measurements Using Time Domain and Spectral Domain

- Optical Coherence Tomography, and Visual Field Sensitivity. *J. Glaucoma*; 20(3): 12-17.
124. **Martinez-Jardon C.S., Meza-de Regil A., Dalma-Weiszhausz J., et al.(2005):** Radial optic neurotomy for ischaemic central vein occlusion. *Br. J. Ophthalmol.*; 89: 558–561.
125. **Maruko I., Iida T., Sekiryu T., and Fujiwara T.(2008):** Early morphological changes and functional abnormalities in group 2a idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry. *Br J Ophthalmol*; 92: 1488-1491.
126. **Massin P., Girach A., Erginay A., Gaudric A.(2006):** Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. *Acta Ophthalmol. Scand.* : 84: 466-474
127. **Mavrofrides E.C., Villate N., Rosenfeld P.J., and Puliafito C.A.(2004):** Age Related Macular Degeneration. In *Optical Coherence Tomography of Ocular Diseases*, 2nd ed. Thorofare, NJ, Slack, 243-343.
128. **Medeiros F.A., Zangwill L.M., Bowd C., et al.(2005):** Evaluation of retinal nerve fiber layer, optic nerve head, and macular thickness measurements for glaucoma detection using optical coherence tomography. *Am J Ophthalmol.*; 139: 44–55.
129. **Menke M.N., Dabov S., and Sturm V.(2008):** Features of age-related macular degeneration assessed with three-dimensional Fourier-domain optical coherence tomography. *Br. J. Ophthalmol.*; 92: 1492–1497.
130. **Meyer C.H., and Toth C.A.(2001):** Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature. *Graefes Arch Clin. Exp. Ophthalmol.*; 239: 325–333.

131. **Michelle L. Gabriele, Gadi Wollstein, Hiroshi Ishikawa, Juan Xu, Jongsick Kim, Larry Kagemann, Lindsey S. Folio, Joel S., and Schuman (2010):** Three dimensional optical coherence tomography imaging: Advantages and advances. *Progress in Retinal and Eye Research*; 223: 69-76.
132. **Michels S, Rosenfeld PJ, Puliafito CA, et al.(2005):** Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. *Ophthalmology*; 112(6): 1035–1047.
133. **Mohammadi K, Bowd C, Weinreb RN, Medeiros FA, Sample PA, Zangwill LM (2004):** Retinal nerve fiber layer thickness measurements with scanning laser polarimetry predict glaucomatous visual field loss. *Am. J. Ophthalmol.*; 138: 592–601.
134. **Moisseiev J, Alhalel A, Masuri R, and Treister G.(1995):** The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. *Arch. Ophthalmol.*; 113: 185–189.
135. **Montero J.M., and Ruiz-Moreno J.M.(2005):** Optical coherence tomography characterization of idiopathic central serous chorioretinopathy. *Br. J. Ophthalmol.*; 89: 562–564.
136. **Munuera JM, Garcia-Layana A, Maldonado MJ, Aliseda D, and Moreno-Montanes J.(1998):** Optical coherence tomography in successful surgery of vitreomacular traction syndrome. *Arch. Ophthalmol.*; 116: 1388–1389.
137. **Nakanishi, H., Hangai, M., Unoki, N., Sakamoto, A., Tsujikawa, A., Kita, M., and Yoshimura, N.(2009):** Spectral-domain optical coherence

- tomography imaging of the detached macula in rhegmatogenous retinal detachment. *Retina*; 29: 232-242.
138. **Niemeijer M., Garvin M.K., Van Ginneken B., Sonka M., and Abr`amoff M.D. (2008):** Vessel segmentation in 3D spectral OCT scans of the retina, in *Proceedings of the SPIE*; 6914: 69141-69143.
139. **Nigam, N., Bartsch, D.U., Cheng, L., Brar, M., Yuson, R.M., Kozak, I., Mojana, F., and Freeman W.R.(2010):** Spectral domain optical coherence tomography for imaging ERM, retinal edema, and vitreomacular interface. *Retina*; 30: 246-253.
140. **Oh J., Smiddy W.E., Flynn Jr. H.W., Gregori G., and Lujan B.(2010):** Photoreceptor inner/outer segment defect imaging by spectral domain OCT and visual prognosis after macular hole surgery. *Invest. Ophthalmol. Vis. Sci.*; 51: 1651-1658.
141. **Ohta K., Sato A., and Fukui E.(2009):** Spectral domain optical coherence tomographic findings at convalescent stage of acute zonal occult outer retinopathy. *Clin. Ophthalmol.*; 3: 423-428.
142. **Ojima T., Tanabe T., Hangai M., et al.(2007):** Measurement of retinal nerve fiber layer thickness and macular volume for glaucoma detection using optical coherence tomography. *Jpn. J. Ophthalmol.*; 51: 197–203.
143. **Ophir A., Martinez M.R., Mosqueda P., and Trevino A.(2010):** Vitreous traction and epiretinal membranes in diabetic macular oedema using spectral-domain optical coherence tomography. *Eye*; 24: 1545-1553.
144. **Ophir A., Trevino A., and Fatum S.(2010):** Extrafoveal vitreous traction associated with diabetic diffuse macular oedema. *Eye*; 24: 347-353.

145. **Otani T, Kishi S, and Maruyama Y.(1999):** Patterns of diabetic macular edema with optical coherence tomography. *Am. J. Ophthalmol.*; 127: 688–693.
146. **Ozdemir H, Karacorlu SA, and Karacorlu M.(2006):** Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. *Am. J. Ophthalmol.*; 141(3): 574–576.
147. **Pai S.A., Shetty R., Vijayan P.B., et al.(2007):** Clinical, anatomic, and electrophysiologic evaluation following intravitreal Bevacizumab for macular edema in retinal vein occlusion. *Am. J. Ophthalmol.*; 143(4): 601-606.
148. **Panozzo G, Gusson E, Parolini B, and Mercanti A.(2003):** Role of OCT in the diagnosis and follow up of diabetic macular edema. *Semin. Ophthalmol.*; 18: 74–81.
149. **Patelli F, Fasolino G, Radice P, et al.(2005):** Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. *Retina*; 25: 840–845.
150. **Penfold PL, Killingsworth MC, and Sarks SH.(1985):** Senile macular degeneration: the involvement of immunocompetent cells. *Graefes Arch Clin Exp. Ophthalmol.*; 223: 69–76.
151. **Podoleanu A.G., and Rosen R.B.(2008):** Combinations of techniques in imaging the retina with high resolution. *Prog Retina Eye Res.*; 27: 464–499.
152. **Pons, M.E., Garcia-Valenzuela, E.,(2005) :** Redefining the limit of the outer retina in optical coherence tomography scans. *Ophthalmology*; 112: 1079–1085.

153. **Puliafito CA, Hee MR, Lin, CP, et al.(1995):** Imaging of macular diseases with optical coherence tomography. *Ophthalmology*; 102: 217–229.
154. **Querques G., Regenbogen M., Soubrane G., and Souied E.H.(2009):** High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy. *Surv. Ophthalmol.*; 54: 311–316.
155. **Ramrath L., Moreno G., Mueller H., Bonin T., Huettmann G., and Schweikard A.(2008):** Towards multi-directional OCT for speckle noise reduction. *Med. Image Comput. Comput. Assist. Interv. Int. Conf. Med. Image Comput. Comput. Assist. Interv.*; 11: 815-823.
156. **Rivellese M, George A, Sulkes D, et al., (2000):** Optical coherence tomography after laser photocoagulation for clinically significant macular edema. *Ophthalmic Surg Lasers*; 31: 192–7.
157. **Roesel M., Henschel A., Heinz C., Dietzel M., Spital G., and Heiligenhaus A.(2009):** Fundus autofluorescence and spectral domain optical coherence tomography in uveitic macular edema. *Graefes Arch Clin. Exp. Ophthalmol.*; 247: 1685–1689.
158. **Rogers A.H., Martidis A., Greenberg P.B., and Puliafito C.A.(2002):** Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. *Am. J. Ophthalmol.*; 134: 566–576.
159. **Roquet W., Roudot-Thoraval F., Coscas G., and Soubrane G.(2004):** Clinical features of drusenoid pigment epithelial detachment in age related macular degeneration. *Br. J. Ophthalmol.*; 88: 638–642.
160. **Rosenfeld P.J., Fung A.E., and Puliafito C.A.(2005):** Optical coherence tomography findings after an intravitreal injection of bevacizumab

- (Avastin) for macular edema from central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging*; 36(4): 336–339.
161. **Sadda S.R., Tan O., Walsh A.C., et al.(2006):** Automated detection of clinically significant macular edema by grid scanning optical coherence tomography. *Ophthalmology*; 113:1187.e1–1187.e12.
162. **Sarks SH, and Sarks JP.(2001):** Age-Related Maculopathy: Nonneovascular Age Related Macular Degeneration and the Evolution of Geographic Atrophy. In *Retina*, 3rd ed. St. Louis, Mosby, 1064–1099.
163. **Sayanagi K., Sharma S., and Kaiser P.K.(2009):** Comparison of retinal thickness measurements between three-dimensional and radial scans on spectral-domain optical coherence tomography. *Am. J. Ophthalmol.*; 148: 431-438.
164. **Schmidt-Erfurth U., Leitgeb R.A., Michels S., et al.(2005):** Three dimensional ultrahigh-resolution optical coherence tomography of macular diseases. *Invest. Ophthalmol. Vis. Sci.*; 46: 3393–3402.
165. **Sebastian Wolf, Ute Wolf-Schnurrbusch(2010):** Spectral-Domain Optical Coherence Tomography Use in Macular Diseases. *Ophthalmologica*; 224: 333-340
166. **Shah NN, Bowed C, Medeiros FA, et al.(2006):** Combining structural and functional testing for detection of glaucoma. *Ophthalmology*; 113: 1593-1602.

167. **Soliman W, Sander B, Soliman KAE-N, et al.(2008):** The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema. *Acta. Ophthalmol.*; 86: 284-291.
168. **Soliman W., Sander B., and Jørgensen T.M.(2007):** Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. *Acta. Ophthalmol. Scand.*; 85: 613-617.
169. **Spaide R.F., Lee J.K., Klancnik J.M., and Gross N.E.(2003):** Optical coherence tomography of branch retinal vein occlusion. *Retina*; 23: 343–347.
170. **Spitzer M.S., Wallenfels-Thilo B., Sierra A., et al.(2006):** Antiproliferative and cytotoxic properties of bevacizumab (Avastin) on different ocular cells. *Br J Ophthalmol*; 90: 1316–1321 .
171. **Srinivasan V.J., Wojtkowski M., Witkin A.J., Duker J.S., Ko T.H., Carvalho M., Schuman J.S., Kowalczyk A., and Fujimoto J.G.(2006):** High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. *Ophthalmology*; 113: 2054.
172. **Stanga P.E., Kychenthal A., Fitzke F.W., et al.(2002):** Retinal pigment epithelium translocation after choroidal neovascular membrane removal in age-related macular degeneration. *Ophthalmology*; 109: 1492–1498.
173. **Starita C., Patel M., Katz B., and Adamis A.P.(2007):** Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen®) in diabetic retinopathy. *Dev. Ophthalmol.*; 39: 122–148.
174. **Strom C., Sander B., Larsen N., et al., (2002)** Diabetic macular edema assessed with optical coherence tomography and stereo fundus photography. *Invest Ophthalmol Vis Sci* ; 43: 241–5.

175. **Submacular Surgery Trials Research Group(2005):** Histopathologic and ultrastructural features of surgically excised subfoveal and choroidal neovascular lesions: Submacular surgery trials report No. 7. Arch. Ophthalmol.; 123: 914-921.
176. **Swanson EA, Izatt JA, Hee MR, et al.(1993):** In-vivo retinal imaging by optical coherence tomography. Opt. Lett.; 18: 1864–1866.
177. **Talks J., Koshy Z., and Chatzinikolas K.(2007):** Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration. Br. J. Ophthalmol.; 91: 600–601 .
178. **Talu S., Balta F., Talu S.D., Merticariu A., and Talu M.(2009):** Fourier Domain - Optical Coherence Tomography in Diagnosing and Monitoring of Retinal Diseases. IFMBE Proceedings; 26: 261-266.
179. **Tan O., Li G., Lu A.T., et al.(2008):** Mapping of macular substructures with optical coherence tomography for glaucoma diagnosis. Ophthalmology; 115: 949-956.
180. **Ting T.D., Oh M., Cox T.A., Meyer C.H., and Toth C.A.(2002):** Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch. Ophthalmol.; 120: 731-737.
181. **Toth C.A., Birngruber R., Boppart S.A., et al.(1997):** Argon laser retinal lesions evaluated in vivo by optical coherence tomography. Am. J. Ophthalmol.; 123: 188-198.
182. **Toth C.A., Narayan D.G., Boppart S.A., et al.(1997):** A comparison of retinal morphology viewed by optical coherence tomography and by light microscopy. Arch. Ophthalmol.; 115: 1425–1428.

183. **Unterhuber A., Povazay B., Hermann B., et al., (2003):** Compact, low-cost Ti:Al₂O₃ laser for in vivo ultrahigh-resolution optical coherence tomography. *Opt. Lett.* 28: 905–907.
184. **Van Velthoven M.E., Faber D.J., Frank D., et al., (2007) :** Recent developments in optical coherence tomography for imaging the retina *Progress in Retinal and Eye Research*; 26: 57–77.
185. **Van Velthoven M.E., Verbraak F.D., Yannuzzi L.A., et al., (2006):** Imaging the retina by enface optical coherence tomography. *Retina* 26, 129–136.
186. **Van Velthoven M.E.J., Van de Linden M.H., De Smet M.D., et al., (2006):** Influence of cataract on optical coherence tomography image quality and retinal thickness. *Br. J. Ophthalmol.* 90, 1259–1262.
187. **Virgili G., Menchini F., Dimastrogiovanni A.F., Rapizzi E., Menchini U., Bandello F., and Chiodini R.G.(2007):** Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular edema: a systematic review. *Invest. Ophthalmol. Vis. Sci.*; 48: 4963–4973.
188. **Vizzeri G., Weinreb R.N., Gonzalez-Garcia A.O., Bowd C., Medeiros F.A., Sample P.A., and Zangwill L.M.(2009):** Agreement between Spectral-Domain and Time-Domain OCT for measuring RNFL thickness. *Br. J. Ophthalmol.*; 93: 775–781.
189. **Wagenblast P.C., Ko T.H., Fujimoto J.G., et al., (2004):** Ultrahigh-resolution optical coherence tomography with a diode-pumped broadband Cr³⁺: LiCAF laser. *Opt. Express.*, 12: 3257–3263.
190. **Wang M, Sander B, Lund Anderson H, and Larsen M.(1999):** Detection of shallow detachments in central serous chorioretinopathy. *Acta. Ophthalmol. Scand.*; 77: 402–405.

191. **Wild S., Roglic G., Green A., et al.(2004):** Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*; 27: 1047–1053.
192. **Wilkins J.R., Puliafito C.A., Hee M.R., et al.(1996):** Characterization of epiretinal membranes using optical coherence tomography. *Ophthalmology*; 103: 2142–2151.
193. **Wojtkowski M., Srinivasan V., Fujimoto J.G., et al.(2005):** Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. *Ophthalmology*; 112: 1734–1746.
194. **Wojtkowski M., Srinivasan V., Ko T., et al.(2004):** Ultrahigh-resolution, high-speed, Fourier domain optical coherence tomography and methods for dispersion compensation. *Opt. Express*; 12: 2404–2422.
195. **Wojtkowski M., Srinivasan V., Ko T., et al.(2005):** High speed, ultrahigh resolution retinal imaging using spectral/Fourier domain OCT. *Conf. Lasers Electrooptics*; 3: 2058–2060.
196. **Wollstein G., Ishikawa H., Wang J., Beaton S.A., and Schuman, J.S., (2005a):** Comparison of three optical coherence tomography scanning areas for detection of glaucomatous damage. *Am. J. Ophthalmol.*; 139: 39-43.
197. **Wollstein G., Schuman J.S., Price L.L., Aydin A., Stark P.C., Hertzmark E., Lai E., Ishikawa H., Mattox C., Fujimoto J.G., and Paunescu, L.A., (2005b):** Optical coherence tomography longitudinal evaluation of retinal nerve fiber layer thickness in glaucoma. *Arch. Ophthalmol.*; 123: 464-470.
198. **Wollstein G., Schuman J.S., Price L.L., et al.(2004):** Optical coherence tomography (OCT) macular and peripapillary retinal nerve fiber layer

- measurements and automated visual fields. *Am. J. Ophthalmol.*; 138: 218-225.
199. **Yannuzzi LA, Negrao S, Iida T, et al.(2001):** Retinal angiomatous proliferation in age-related macular degeneration. *Retina*; 21: 416–434.
200. **Yeung L., Lima V.C., Garcia P., Landa G., and Rosen R.B.(2009):** Correlation between spectral domain optical coherence tomography findings and fluorescein angiography patterns in diabetic macular edema. *Ophthalmology*; 116: 1158–1167.
201. **Yi K., Mujat M., Park B.H., Sun W., Miller J.W., Seddon J.M., Young L.H., de Boer J.F., Chen T.C.,(2009):** Spectral domain optical coherence tomography for quantitative evaluation of drusen and associated structural changes in nonneovascular age-related macular degeneration. *Br. J. Ophthalmol.*; 93: 176-181.
202. **Yoganathan P., Deramo V.A., Lai J.C., et al.(2006):** Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. *Retina*; 26(9): 994-998.
203. **Zacks D.N., and Johnson M.W.(2004):** Retinal angiomatous proliferation: optical coherence tomographic confirmation of an intraretinal lesion. *Arch. Ophthalmol.*; 122: 932-933.
204. **Zangwill L.M., Weinreb R.N., Beiser J.A., Berry C.C., Cioffi G.A., Coleman A.L., Trick G., Liebmann J.M., Brandt J.D., Piltz-Seymour J.R., Dirkes K.A., Vega S., Kass M.A., and Gordon M.O.(2005):** Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch. Ophthalmol.*; 123: 1188-1197.

205. **Zeimer R., Asrani S., Zou S., et al.(1998):** Quantitative detection of glaucomatous damage at the posterior pole by retinal thickness mapping. A pilot study. *Ophthalmology*; 105: 224-231.
206. **Zeimer R., Shahidi M., Mori M., et al.(1996):** A new method for rapid mapping of the retinal thickness at the posterior pole. *Invest Ophthalmol Vis Sci.*; 37: 1994–2001.
207. **Zolf R., Glacet-Bernard A., Benhamou N., Mimoun G., Coscas G., and Soubrane G.(2002):** Imaging analysis with optical coherence tomography: relevance for submacular surgery in high myopia and in multifocal choroiditis. *Retina*; 22: 192–201.